Follow-up time and events of breast cancer patients by lipid-lowering drug use at recruitment.

<p>Follow-up time and events of breast cancer patients by lipid-lowering drug use at recruitment.</p

Baseline tumor and treatment characteristics of breast cancer patients by lipid-lowering drug use at recruitment.

<p>Baseline tumor and treatment characteristics of breast cancer patients by lipid-lowering drug use at recruitment.</p

Hazard ratios for mortality and recurrence associated with lipid-lowering drug use at recruitment, compared to past or never use.

*<p>stratified by region, adjusted for age.</p>**<p>stratified by region, tumor grade, estrogen/progesterone receptor status; adjusted for age, the traditional prognostic factors tumor size, nodal status, (metastases, stage I–IV only), and for the following additional covariates evaluated using backward elimination: menopausal hormone treatment at recruitment, mode of detection, radiotherapy, and smoking. Mortality analyses are additionally adjusted for cardiovascular disease, diabetes mellitus, and body-mass index.</p

Additional file 5: Table S2. of A polymorphism in the base excision repair gene PARP2 is associated with differential prognosis by chemotherapy among postmenopausal breast cancer patients

Associations between SNP and breast cancer-specific mortality by radiotherapy for interactions showing p <0.1 (LRT)$ in the MARIE study and results of replication in BCAC studies. (DOCX 20 kb

Additional file 3: Figure S2. of A polymorphism in the base excision repair gene PARP2 is associated with differential prognosis by chemotherapy among postmenopausal breast cancer patients

Meta-analysis across BCAC studies of PARP2 and breast cancer prognosis. Forest plot of the combined hazard ratios and 95 % confidence intervals for PARP2 rs878156 in the discovery MARIE study and the replication studies in Breast Cancer Association Consortium (BCAC) using fixed effect models, according to treatment, i.e. no chemotherapy (A), any type of chemotherapy (B), and anthracycline-based chemotherapy (C). The combined effects for the BCAC studies were also based on fixed effect models. (DOCX 996 kb

rs11977670, chromosome 7:139942304 G>A, and association ILC in populations of European ancestry.

<p>rs11977670, chromosome 7:139942304 G>A, and association ILC in populations of European ancestry.</p

Forest plot for rs11977670.

<p>Forest plot for rs11977670.</p

SNPs associated with ILC (P<5×10⁻⁸) or LCIS (P<0.05) in a pooled lobular analysis (GLACIER and BCAC).

<p>SNPs associated with ILC (P<5×10⁻⁸) or LCIS (P<0.05) in a pooled lobular analysis (GLACIER and BCAC).</p

SNPs showing differential lobular and ductal associations with breast cancer risk in BCAC subjects (ER+ tumours only).

<p>SNPs showing differential lobular and ductal associations with breast cancer risk in BCAC subjects (ER+ tumours only).</p

Association with risk of breast cancer for rs11977670 stratified by breast cancer tumour subtypes (Pooled analysis, BCAC, GLACIER, UK PHASE II).

<p>Association with risk of breast cancer for rs11977670 stratified by breast cancer tumour subtypes (Pooled analysis, BCAC, GLACIER, UK PHASE II).</p